Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

286 – Safety and Immunogenicity of Autologous DC Vaccines Loaded With Autologous HIV or Conserved Peptides

By Jimmy He PharmD, DScMarch 31, 2026

…a1DC), and pulsed with 1 of 2 antigen sources (HIVconsvX conserved pol/gag peptides or autologous inactivated HIV-1) or no antigen (control). Methods Eligible participants (ppts) were adults with HIV RNA…

121 – Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24

By Jimmy He PharmD, DScMarch 20, 2025

…fiscal years, FY21 – FY24.   Methods We analyzed PEPFAR Monitoring, Evaluation, and Reporting data for all CLHIV <15 yo on ART with IIT between October 2020 and June 2024 (FY21-FY24)…

ON DEMAND POST EXPOSURE PROPHYLAXIS WITH DOXYCYCLINE FOR MSM ENROLLED IN A PREP TRIAL

By Enthusiast Inc MDFebruary 15, 2017

…8 pts (7%) discontinuing PEP because of gastro-intestinal adverse events (AEs). Gastrointestinal AEs were reported in 61 pts (53%) and 47 pts (41%) in the PEP and no PEP arms,…

1351 – Early PEPFAR Implementation of Cabotegravir-LA and Implications for Long-Acting HIV Prevention

By Jimmy He PharmD, DScApril 18, 2025

…curb new HIV infections globally. In 2024, PEPFAR-supported injectable cabotegravir (CAB-LA) was introduced to expand HIV prevention options in five initial countries. Methods CAB-LA was introduced in 105 facilities in…

POTENTIAL IMPACT & COST-EFFECTIVENESS OF WIDELY ACCESSIBLE TLD IN SUB-SAHARAN AFRICA

By Jimmy He PharmD, DScMarch 3, 2023

…to enable PEP use within 24 hours of sex. Giving unrestricted access would mean drugs might also be used as PrEP, and as ART for people with HIV, without engagement…

1114 – HIV PrEP Product Preferences Among Clients Using Oral PrEP and PEP at Private Pharmacies in Kenya

By Jimmy He PharmD, DScMarch 31, 2026

…private pharmacies, may help enhance PrEP reach and coverage. We assessed PrEP product preferences among clients obtaining daily oral PrEP or post-exposure prophylaxis (PEP) at private pharmacies in Kenya. Methods…

MHC-E Presentation Mediates SIV-Specific NK Cell Responses in SIV-Infected Rhesus Macaques

By Jimmy He PharmD, DScApril 26, 2024

…virus via antigen-specific memory NK responses. Methods: To study antigen-specific NK cells in NHP, we developed a novel in vitro method to clonally expand single rhesus macaque (RM) NK cells…

PBPK MODELS OF TFV EXPOSURE IN LYMPH NODES REVEAL PERMEABILITY-LIMITED DISTRIBUTION

By Jimmy He PharmD, DScApril 22, 2021

…MoBi, where a lymph node compartment was added. Physiologic parameters describing the lymph node were obtained from literature. The lymph node model was exported back to PK-Sim, and fit to…

368 – Elevated Lymph Node Metabolic Activity During Long-Term Antiretroviral Therapy

By Jimmy He PharmD, DScApril 18, 2025

…Medical Image Merge Software (MIM®). Cervical, mediastinal, axillary, and inguinal lymph nodes were identified manually and verified by a board-certified Nuclear Medicine radiologist. Metabolic activity in lymph nodes was quantified…

CROSS-RECOGNITION OF A CONSERVED CD4+ T-CELL EPITOPE PRESENT IN DIVERSE CORONAVIRUSES

By Jimmy He PharmD, DScApril 4, 2022

…T cell responses to S815-827. All responders also recognized homologous peptides from at least 2 other coronaviruses, and 8 out of 11 responders recognized peptides from at least 6 out…

←1
23456789
…1011121314…
1516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top